Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies
Authors:
- 1 June 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 31 (4) , 182-186
Abstract
Purpose of review: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a new strategy to reduce LDL cholesterol (LDL-C), that is currently pursued by mAbs. A promising novel approach to target PCSK9 is using small interfering RNAs to inhibit hepatic PCSK9 synthesis. The first small interfering RNA developed for this purpose is inclisiran. Here, we review its clinical trial data and potential impact on patient management. Recent findings: Inclisiran achieves sustained, additional 50% LDL-C reduction in patients receiving background statin therapy. Resulting LDL-C changes can be maintained by an infrequent dosing regimen with twice per year injections, that appear safe and well tolerated. Thus far, inclisiran has been studied in patients with established cardiovascular disease, high-risk primary prevention and in patients with familial hypercholesterolemia. Summary: High and very high-risk individuals may benefit from the additional LDL-C-lowering effect of inclisiran when added to current lipid-lowering therapies. Furthermore, the simple dosing regimen may improve the convenience for users and facilitate patient adherence to therapy. The safety and convenience of inclisiran may offer new opportunities for population health.Keywords
This publication has 19 references indexed in Scilit:
- Recent Advances in Developing PCSK9 Inhibitors for lipid-lowering TherapyFuture Medicinal Chemistry, 2019
- Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low LevelsJAMA Cardiology, 2018
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialThe Lancet, 2017
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 2017
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL CholesterolNew England Journal of Medicine, 2017
- Reductions in Atherogenic Lipids and Major Cardiovascular EventsCirculation, 2016
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene SilencingJournal of the American Chemical Society, 2014
- PCSK9: a convertase that coordinates LDL catabolismJournal of Lipid Research, 2009
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteThe American Journal of Human Genetics, 2006
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin TherapyJACC, 2005